Welcome to our dedicated page for Vericel news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel stock.
Vericel Corporation develops and markets advanced therapies for sports medicine and severe burn care, with U.S. commercial products that include MACI, Epicel and NexoBrid. News about VCEL commonly covers financial results, MACI procedure and surgeon activity, burn care revenue trends, and manufacturing capacity for cell therapy products.
Company updates also include regulatory and operational milestones, such as FDA approval of commercial MACI manufacturing at Vericel's advanced therapy facility, as well as BARDA-supported procurement and development activities for NexoBrid. The recurring themes center on commercialization, specialty biologics supply, product access and development within Vericel's cellular therapy portfolio.
Vericel (NASDAQ:VCEL) reported Q1 2026 results: total revenue $68.4M (+30%), MACI $56.4M (+22%), Burn Care $12.0M (+91%), gross margin 72%, adjusted EBITDA $9.6M (+195%), free cash flow $15.1M, and cash & investments ~$211M with no debt. The company raised 2026 revenue guidance to $326–$336M and reaffirmed ~75% gross margin and ~27% adjusted EBITDA margin.
Vericel (NASDAQ:VCEL) will report first-quarter 2026 financial results on Thursday, May 7, 2026. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss results and business highlights.
Presentation slides will be available on the Investor Relations website and a replay of the webcast will be accessible until May 7, 2027. Telephone participants can dial the provided U.S. and international numbers and enter passcode 244506.
Vericel (NASDAQ:VCEL) received a ten-year BARDA contract valued at up to $197 million, effective April 1, 2026. The agreement includes a $35 million base period and about $10 million for initial procurement and Vendor Managed Inventory (VMI) over 12 months.
The contract covers procurement of NexoBrid, VMI establishment, design/validation of a potential U.S. manufacturing facility, and development of a room-temperature stable formulation and an expanded blast trauma indication.
Vericel (NASDAQ:VCEL) announced FDA approval to commercially manufacture MACI at its new Burlington, Massachusetts cell therapy facility. The approval permits commercial production to begin in Q2 2026, increases manufacturing capacity to support long-term growth, and enables potential MACI commercialization outside the U.S.
This milestone strengthens the company’s supply chain and positions Vericel to scale MACI production to meet rising demand for restorative cartilage repair therapies.
Vericel (NASDAQ:VCEL) will present at multiple investor conferences in March 2026. The company confirmed presentations at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, and the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026.
A webcast of the presentations will be available via the company's investor relations website.
Vericel (NASDAQ:VCEL) reported strong fourth-quarter and full-year 2025 results: total revenue $276.3M, MACI revenue $239.5M (+21% YoY), and record Q4 gross margin of 79%. Full-year adjusted EBITDA rose to $70.9M (26% margin) and the company holds approximately $200M cash with no debt. Management provided 2026 guidance: total revenue of $316–$326M, MACI revenue of $280–$286M, and ~75% gross margin.
Q4 highlights included record MACI implants and salesforce expansion; the company remains on track for commercial manufacturing and a UK MHRA submission in 2026.
Vericel (NASDAQ:VCEL) will report fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026.
Management will host a conference call and webcast at 8:30 a.m. ET. Presentation slides will be available on the Investor Relations website and a replay will be available through February 26, 2027. Telephone participants may dial 800-330-6730 or +1-312-471-1351 with passcode 227995.
Vericel (NASDAQ:VCEL) reported preliminary, unaudited 2025 results: total revenue ~$276 million comprising MACI revenue $239.5 million and Burn Care $36.5 million. Gross margin is expected at 74% and adjusted EBITDA margin at 26%. The company expects GAAP net income for the second consecutive year and ended the period with $200 million cash and investments and no debt. Q4 marks the highest quarterly counts since launch for MACI implants, implanting surgeons, surgeons taking biopsies, and MACI biopsies, with MACI revenue growth of 20%+ for a third straight year. Completed MACI sales force expansion, >900 MACI Arthro trained surgeons, initiated the MACI Ankle MASCOT study, and remain on track to begin commercial manufacturing at a new facility in 2026.
Vericel (NASDAQ:VCEL) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 2:15 p.m. ET (11:15 a.m. PT).
A live webcast of the presentation will be available on the company’s Investor Relations website at http://investors.vcel.com.
Vericel (NASDAQ:VCEL) will present a fireside chat at the Stephens Annual Investment Conference on Thursday, November 20, 2025 at 11:00 a.m. ET (10:00 a.m. CT).
A live webcast will be available via the company’s Investor Relations website at http://investors.vcel.com, allowing investors and analysts to view the presentation in real time.